重温贝塔阻断剂与牛皮之间的联系:来自现实世界的数据的证据
Xiulan Zheng1, Jian Sun2, Zhen Wang3
1School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, Macau, China.
Endocrine, metabolic & immune disorders drug targets
|August 28, 2025
概括
与一些报告相反,使用β-阻断剂似乎不会增加牛皮的风险. 这项研究没有发现显著的关联,这表明目前的临床标签可能不合适.
科学领域:
- 药理学
- 皮肤病学
- 流行病学
背景情况:
- 贝塔抑制剂有时与牛皮的发展或恶化有关.
- 现有的药物流行病学研究对这一关联提出了相互矛盾的结果.
研究的目的:
- 调查使用β抑制剂与患上牛皮的风险之间的潜在关联.
- 为了澄清之前的药物流行病学研究的相互矛盾结果.
主要方法:
- 使用美国国家健康和营养检查调查 (NHANES) 数据库的观察研究.
- 倾向性得分匹配和多变量逻辑回归分析.
- 对FDA不良事件报告系统 (FAERS) 数据库的不成比例分析.
- 两个样本的孟德尔随机化 (MR) 研究.
主要成果:
- 对NHANES数据的逻辑回归显示,β阻断剂使用与牛皮风险之间没有显著的关联 (OR: 1.49, p=0. 250).
- 在FAERS分析中,没有关于牛皮的β抑制剂的强有力的安全信号 (ROR: 0. 34).
- 对MR结果的分析表明,使用β阻断剂与减少牛皮风险之间存在统计学意义上的关联 (OR: 0. 9985, p< 0. 001).
结论:
- 这种流行病学关联很可能是由于混因素造成的,例如β- 阻断剂的心血管征兆.
- 神经免疫通路提供了生物学上可信但复杂的机制,
- 贝塔抑制剂不会显著增加牛皮的风险,因此将其标记为药物诱导的牛皮的原因可能是不合适的.
相关概念视频
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
970
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
970
01:28Antihypertensive Drugs: Types of β-Blockers
863
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
863
01:25Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers
753
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
753
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
597
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
597
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:17Antihypertensive Drugs: Action of β1 Blockers
609
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
609